Brainstorm Cell Therapeutics Beheer

Beheer criteriumcontroles 1/4

De CEO Brainstorm Cell Therapeutics is Chaim Lebovits, benoemd in Jan2023, heeft een ambtstermijn van 1.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.13M, bestaande uit 39.1% salaris en 60.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.42% van de aandelen van het bedrijf, ter waarde € 133.33K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 6.7 jaar.

Belangrijke informatie

Chaim Lebovits

Algemeen directeur

US$1.1m

Totale compensatie

Percentage CEO-salaris	39.1%
Dienstverband CEO	1.8yrs
Eigendom CEO	1.4%
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	6.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Chaim Lebovits's beloning veranderd ten opzichte van Brainstorm Cell Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$14m
Jun 30 2024	n/a	n/a	-US$13m
Mar 31 2024	n/a	n/a	-US$16m
Dec 31 2023	US$1m	US$442k	-US$17m
Sep 30 2023	n/a	n/a	-US$17m
Jun 30 2023	n/a	n/a	-US$22m
Mar 31 2023	n/a	n/a	-US$24m
Dec 31 2022	US$1m	US$500k	-US$24m
Sep 30 2022	n/a	n/a	-US$25m
Jun 30 2022	n/a	n/a	-US$24m
Mar 31 2022	n/a	n/a	-US$23m
Dec 31 2021	US$1m	US$500k	-US$24m
Sep 30 2021	n/a	n/a	-US$30m
Jun 30 2021	n/a	n/a	-US$29m
Mar 31 2021	n/a	n/a	-US$30m
Dec 31 2020	US$2m	US$500k	-US$32m
Sep 30 2020	n/a	n/a	-US$28m
Jun 30 2020	n/a	n/a	-US$29m
Mar 31 2020	n/a	n/a	-US$26m
Dec 31 2019	US$1m	US$500k	-US$23m
Sep 30 2019	n/a	n/a	-US$21m
Jun 30 2019	n/a	n/a	-US$18m
Mar 31 2019	n/a	n/a	-US$17m
Dec 31 2018	US$2m	US$500k	-US$14m
Sep 30 2018	n/a	n/a	-US$8m
Jun 30 2018	n/a	n/a	-US$8m
Mar 31 2018	n/a	n/a	-US$5m
Dec 31 2017	US$1m	US$391k	-US$5m

Compensatie versus markt: De totale vergoeding ($USD 1.13M ) Chaim } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 476.59K ).

Compensatie versus inkomsten: De vergoeding van Chaim is gestegen terwijl het bedrijf verliesgevend is.

CEO

Chaim Lebovits (53 yo)

1.8yrs

Tenure

US$1,128,795

Compensatie

Mr. Chaim Lebovits is President & Chief Executive Officer of Brainstorm Cell Therapeutics Inc. from January 2023. Mr. Lebovits was Chief Executive Officer of Brainstorm Cell Therapeutics Inc. from April 20...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Chaim Lebovits	President & CEO	1.8yrs	US$1.13m	1.42% € 133.3k
Irit Arbel	Co-Founder & Independent Vice Chair of the Board	20.5yrs	geen gegevens	0.18% € 17.1k
Alla Patlis	Interim CFO & Controller	11.9yrs	US$146.78k	0.076% € 7.2k
Uri Yablonka	Executive VP	7.7yrs	US$247.06k	0.15% € 13.9k
Hartoun Hartounian	Executive VP & COO	less than a year	geen gegevens	geen gegevens
Daniel Offen	Chief Scientific Advisor	no data	geen gegevens	geen gegevens
Mary Turner	Senior Vice President of Patient Advocacy & Government Affairs	2.8yrs	geen gegevens	geen gegevens
Ibrahim Dagher	Executive VP & Chief Medical Officer	1.3yrs	geen gegevens	0.22% € 20.9k
Netta Blondheim-Shraga	Senior Vice President of Research and Development	less than a year	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van GHD wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Irit Arbel	Co-Founder & Independent Vice Chair of the Board	20.5yrs	geen gegevens	0.18% € 17.1k
Uri Yablonka	Executive VP	10.4yrs	US$247.06k	0.15% € 13.9k
Jacob Frenkel	Independent Chairman of the Board	4.7yrs	geen gegevens	0.066% € 6.2k
Stanley Appel	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Andrew Card	Member of Business Advisory Board	13.7yrs	geen gegevens	geen gegevens
Amit Bar-Or	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Rasheda Ali	Member of Business Advisory Board	17.1yrs	geen gegevens	geen gegevens
Jerold Chun	Chairman of Scientific Advisory Board	6.7yrs	geen gegevens	geen gegevens
Anthony Polverino	Independent Director	6.8yrs	US$12.50k	0.030% € 2.9k
Ralph Kern	Member of Scientific Advisory Board	1.8yrs	US$4.46m	geen gegevens
Stacy Lindborg	Director	less than a year	US$1.01m	0.42% € 39.8k
Nir Naor	Independent Director	1.4yrs	geen gegevens	geen gegevens

6.7yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van GHD wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.7 jaar).

Brainstorm Cell Therapeutics Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Brainstorm Cell Therapeutics Inc., Annual General Meeting, Sep 16, 2024

Brainstorm Cell Therapeutics Announces Appointment of Haro Hartounian as EVP and COO

Brainstorm Cell Therapeutics Inc. Announces Management Changes

Brainstorm Cell Therapeutics Inc. Announces Executive Changes

Brainstorm Cell Therapeutics Inc., Annual General Meeting, Dec 18, 2023

BrainStorm Cell Therapeutics Inc. Appoints Bob Dagher as Executive Vice President and Chief Development Officer

Recent updates

Brainstorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Brainstorm Cell Therapeutics Implements 1-for-15 Reverse Stock Split to Meet Nasdaq's Minimum Bid Price Requirement

Brainstorm Cell Therapeutics Inc., Annual General Meeting, Sep 16, 2024

Brainstorm Cell Therapeutics Receives Deficiency Notice from Nasdaq Due to Non-Compliance with the Minimum of $35 Million Market Value of Listed Securities Pursuant to Nasdaq Listing Rule 5550(b)(2)

Brainstorm Cell Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $4 million.

Brainstorm Cell Therapeutics Inc. Reaches Alignment with Fda on Cmc Aspects of Phase 3B Nurown®? Clinical Trial

New major risk - Revenue and earnings growth

Brainstorm Cell Therapeutics Announces Appointment of Haro Hartounian as EVP and COO

Brainstorm Cell Therapeutics Inc. Announces Non-Compliance Update

Brainstorm Cell Therapeutics Receives Staff Determination Letter from Nasdaq Regarding it Not Regains Compliance with the Minimum Bid Price Requirement by April 29, 2024 and Submits a Hearing Request to the Nasdaq Hearings Panel to Appeal the Staff’s Determination

Brainstorm Cell Therapeutics Inc. Announces Management Changes

BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule

BrainStorm Cell Therapeutics Inc. Announces Agreement with FDA on Special Protocol Assessment for Phase 3b Trial in ALS

New major risk - Shareholder dilution

BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn in ALS

Brainstorm Cell Therapeutics Inc. Announces Executive Changes

BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS

Brainstorm Cell Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance Market Value of Listed Securities Requirement for Continued Listing on The Nasdaq Capital Market

Brainstorm Cell Therapeutics Inc., Annual General Meeting, Dec 18, 2023

Brainstorm Cell Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

Brainstorm Cell Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

Brainstorm Cell Therapeutics Receives Non-Compliance Notice from Nasdaq

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc

BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn for the Treatment of ALS

New minor risk - Profitability

Brainstorm Cell Therapeutics Inc. to Report Q2, 2023 Results on Aug 14, 2023

BrainStorm Cell Therapeutics Inc. Appoints Bob Dagher as Executive Vice President and Chief Development Officer

Brainstorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair

New minor risk - Market cap size

Forecast to breakeven in 2025

Brainstorm Cell Therapeutics Inc Announces Resignation of David Setboun as Executive Vice President and Chief Operating Officer

Forecast to breakeven in 2025

No longer forecast to breakeven

BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer

Brainstorm Cell Therapeutics Inc. Announces Type A Meeting with FDA Granted for NurOwn®

Brainstorm Cell Therapeutics Inc., Annual General Meeting, Jan 10, 2023

BrainStorm Cell Therapeutics Submits Type A Meeting Request to U.S. Food and Drug Administration

Brainstorm Cell Therapeutics Seeks FDA Approval of Mesenchymal Stem Cell Therapy Called NurOwn for the Treatment of ALS

Brainstorm Cell Therapeutics Inc. Receives Refusal to File Letter from FA for Its New Biologics License Application for Nurown for the Treatment of Als

BrainStorm Presents New Biomarker Analyses from NurOwn's Phase 3 ALS Trial at the ALS ONE Research Symposium

Brainstorm Cell Therapeutics Inc. Announces Peer Reviewed Publication of Results from the Nurown Phase 2 Progressive MS Trial in Multiple Sclerosis Journal

Brainstorm Cell Therapeutics Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for NurOwn for the Treatment of Amyotrophic Lateral Sclerosis

Brainstorm Cell Therapeutics Inc. Appoints Antal Pearl-Lendner as Chief Legal Counsel

BrainStorm Cell Therapeutics Inc. Announces Presentation of Nurown® Exosome Preclinical Data At ISCT 2022 San Francisco Meeting

U.S. Food and Drug Administration Authorizes Further Brainstorm Cell Therapeutics Inc.'s Nurown Dosing Under Expanded Access Program

Brainstorm Cell Therapeutics Announces Peer Reviewed Publication of Nurown's® Phase 3 Study for Als in Muscle and Nerve

BrainStorm Cell Therapeutics Announces the Presentation of New Analyses from the Phase 3 Trial of NurOwn® in ALS at the 4th Annual ALS ONE Research Symposium

No longer forecast to breakeven

Brainstorm Cell Therapeutics Inc.(NasdaqCM:BCLI) dropped from Russell 3000 Growth Index

New 90-day low: €3.28

Brainstorm Cell Therapeutics Inc. Announces High-Level FDA Feedback on NurOwn® ALS Clinical Development Program

Brainstorm Cell Therapeutics Inc. Announces Feedback from FDA Type-C Meeting on Future NurOwn® Manufacturing Plan

Brainstorm Cell Therapeutics Inc. to Report Q4, 2020 Results on Feb 04, 2021

BrainStorm Announces the Publication of Preclinical Data Highlighting the Potential of a NurOwn® Derived Exosome-Based Treatment for COVID-19 ARDS

Brainstorm Cell Therapeutics Inc. Announces Completion of All Dosing in NurOwn® Phase 2 MS Study

BrainStorm Announces NurOwn® Expanded Access Program

New 90-day low: €3.42

BrainStorm Cell Therapeutics Inc. Announces Topline Results from NurOwn® Phase 3 ALS Study

New 90-day high: €14.80

Brainstorm Cell Therapeutics Inc. Appoints William K. White as Senior Vice President, Head of Market Access & Pricing

Brainstorm Cell Therapeutics Inc. to Report Q2, 2020 Results on Aug 03, 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden